Management guidance · Q4 FY26 call
Leading Healthcare Services companies on guidance
Sign up free to see every company in the sector ranking and track Invicta Diagnostic Ltd.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Invicta Diagnostic Ltd
Quarter-by-quarter operating performance
Financials of Invicta Diagnostic Ltd
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 7.46 | 7.99 | 30.10 | 32.35 |
| Expenses + | 4.22 | 4.59 | 21.09 | 22.58 |
| Operating Profit | 3.24 | 3.40 | 9.01 | 9.77 |
| OPM % | 43.43% | 42.55% | 29.93% | 30.20% |
| Other Income + | 0.00 | 0.35 | 0.57 | 0.69 |
| Interest | 0.02 | 0.08 | 0.23 | 0.20 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| Profit before tax | 2.27 | 2.69 | 6.86 | 7.01 |
| Tax % | 22.91% | 0.00% | 31.63% | 30.39% |
| Net Profit + | 1.76 | 2.69 | 4.69 | 4.88 |
| EPS in Rs | 204.56 | 5.57 | 3.91 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Invicta Diagnostic Ltd
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.13 | 8.42 | 12.57 | |
| Reserves | 12.05 | 8.41 | 37.35 | |
| Borrowings + | 1.87 | 1.67 | 3.67 | |
| Other Liabilities + | 1.79 | 2.75 | 6.66 | |
| Total Liabilities | 15.84 | 21.25 | 60.25 | |
| Fixed Assets + | 11.78 | 9.62 | 19.20 | |
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 4.33 | 6.20 | |
| Other Assets + | 4.06 | 7.30 | 34.85 | |
| Total Assets | 15.84 | 21.25 | 60.25 |
Financials of Invicta Diagnostic Ltd
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 4.21 | 6.47 | 2.93 | |
| Cash from Investing Activity + | -10.01 | -5.23 | -13.67 | |
| Cash from Financing Activity + | 7.14 | -0.42 | 30.79 | |
| Net Cash Flow | 1.34 | 0.83 | 20.05 | |
| Free Cash Flow | -8.56 | 6.15 | -9.93 | |
| CFO/OP | 124% | 72% | 40% |
Financials of Invicta Diagnostic Ltd
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 37.46 | 17.70 | 6.43 | |
| Inventory Days | 296.56 | 83.33 | 78.88 | |
| Days Payable | 1,102.60 | 70.00 | 254.03 | |
| Cash Conversion Cycle | -768.58 | 31.04 | -168.72 | |
| Working Capital Days | 5.94 | 21.58 | 55.74 | |
| ROCE % | 46.45% | 20.28% |
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.